Relevance of systems pharmacology in drug discovery

被引：32

作者：

Cucurull-Sanchez, Lourdes ^{[1
]}

Spink, Karen G. ^{[2
]}

Moschos, Sterghios Athanasios ^{[2
,3
]}

机构：

[1] Pfizer PGRD, Translat Res, Dept Pharmacokinet Dynam & Metab, Sandwich CT13 9NJ, Kent, England

[2] Pfizer PGRD, Epigenet & Regenerat Med, Sandwich CT13 9NJ, Kent, England

[3] Univ Westminster, Sch Life Sci, London W1W 6UW, England

来源：

DRUG DISCOVERY TODAY | 2012年 / 17卷 / 13-14期

关键词：

NEGATIVE FEEDBACK; TEMPORAL CONTROL; GENE-EXPRESSION; ATTRITION; SPECIFICITY; DYNAMICS; LESSONS; PKPD;

D O I：

10.1016/j.drudis.2012.01.015

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The pharmaceutical industry is in the process of re-inventing its pipeline in an attempt to overcome its increasing phase II and III attrition rates. Here, we describe how systems pharmacology can be used as a risk assessment tool to alleviate this problem before bringing in larger investments. We propose that this translational research tool could provide a valuable, complementary addition to other emerging innovative approaches for target identification and validation in discovery and, ultimately, for aiding clinical trial optimization.

引用

页码：665 / 670

页数：6

共 35 条

[1] RETRACTED: Kinase inhibitors and airway inflammation (Retracted article. See vol. 683, pg. 340, 2012) [J].

Adcock, IM ;

Chung, KF ;

Caramori, G ;

Ito, K .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2006, 533 (1-3) :118-132

[2] Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].

Amado, Rafael G. ;

Wolf, Michael ;

Peeters, Marc ;

Van Cutsem, Eric ;

Siena, Salvatore ;

Freeman, Daniel J. ;

Juan, Todd ;

Sikorski, Robert ;

Suggs, Sid ;

Radinsky, Robert ;

Patterson, Scott D. ;

Chang, David D. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634

[3]

[Anonymous], 2011, NAT REV DRUG DISCOV, V10, P889

[4] Systems Clinical Pharmacology [J].

Atkinson, A. J., Jr. ;

Lyster, P. M. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (01) :3-6

[5]

Bakhtiar Ray, 2008, Journal of Pharmacological and Toxicological Methods, V57, P85, DOI 10.1016/j.vascn.2007.10.002

[6] New Therapies for Chronic Obstructive Pulmonary Disease [J].

Barnes, Peter J. .

MEDICAL PRINCIPLES AND PRACTICE, 2010, 19 (05) :330-338

[7] Novel signal transduction modulators for the treatment of airway diseases [J].

Barnes, PJ .

PHARMACOLOGY & THERAPEUTICS, 2006, 109 (1-2) :238-245

[8] Proof of Concept: A PhRMA Position Paper With Recommendations for Best Practice [J].

Cartwright, M. E. ;

Cohen, S. ;

Fleishaker, J. C. ;

Madani, S. ;

McLeod, J. F. ;

Musser, B. ;

Williams, S. A. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 (03) :278-285

[9] Transient IκB kinase activity mediates temporal NF-κB dynamics in response to a wide range of tumor necrosis factor-αdoses [J].

Cheong, R ;

Bergmann, A ;

Werner, SL ;

Regal, J ;

Hoffmann, A ;

Levchenko, A .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (05) :2945-2950

[10] Understanding NF-κB signaling via mathematical modeling [J].

Cheong, Raymond ;

Hoffmann, Alexander ;

Levchenko, Andre .

MOLECULAR SYSTEMS BIOLOGY, 2008, 4 (1)

← 1 2 3 4 →